AffaMed Therapeutics Announces Partner Vistagen Reports Top-Line Results From Phase 3 PALISADE-2 Trial Of Fasedienol Nasal Spray In Social Anxiety Disorder
Portfolio Pulse from Happy Mohamed
AffaMed Therapeutics and its partner Vistagen Therapeutics (NASDAQ:VTGN) have reported positive top-line results from the Phase 3 PALISADE-2 trial of fasedienol nasal spray for social anxiety disorder. The trial met its primary and secondary endpoints, demonstrating a significant reduction in patient-reported distress and a significant difference in the proportion of responders compared to placebo. The companies plan to commercialize the product in China, South Korea, and Southeast Asia.
August 10, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen Therapeutics' successful Phase 3 trial results for fasedienol nasal spray could potentially boost its stock in the short term. The positive results and the potential market in Asia could attract investor interest.
Positive clinical trial results often lead to increased investor confidence and can boost a company's stock price. The potential market in Asia for the product could also attract investors, given the large population and the growing awareness and treatment of mental health disorders in the region.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100